Article

Importance of Yoga Research

Author(s):

Onclive Team

Scientific research documenting the effects of yoga practice on the health of people living with cancer is an exciting world to explore.

Scientific research documenting the effects of yoga practice on the health of people living with cancer is an exciting world to explore. Many outstanding scientists are applying the yoga practices of asana, breathing, and meditation to the care of people with cancer, helping them alleviate fatigue and improve their quality of life.

This video briefly discusses the outcomes of an analysis conducted on a number of published studies that tested yoga on people living with cancer. The link to this article is given below. Please watch the video, read the article, and then post your comments. Future blog postings will describe single studies involving yoga in adults with cancer.

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on final overall survival data from the KEYNOTE-811 trial.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on data for neoadjuvant nivolumab plus ipilimumab in dMMR colon cancer.
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Related Content
Douglas W. Sborov, MD, MS
October 28th 2024

CAR T-Cell Therapies Extend Treatment-Free Intervals in Multiple Myeloma With Regular Toxicity Monitoring

David R. Gandara, MD, chief medical officer, International Society of Liquid Biopsy; co-director, Center for Experimental Therapeutics in Cancer, senior advisor to the director, University of California Davis Comprehensive Cancer Center; adjunct clinical professor, Translational and Clinical Research Program, University of Hawaii Cancer Center
October 28th 2024

Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing: With David R. Gandara, MD

Courtney DiNardo, MD, MSCE, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
October 28th 2024

Rezatapopt Monotherapy Remains Under Study Following Discontinuation of Combination Cohort in TP53+ Solid Tumors

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
October 24th 2024

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

RMC-9805 was proven safe and active in patients with previously treated, KRAS G12D–mutant pancreatic ductal adenocarcinoma.
October 28th 2024

RMC-9805 Triggers Tumor Regressions in KRAS G12D–Mutant Pancreatic Cancer

Nataliya Uboha, MD, PhD, of Wisconsin School of Medicine
October 28th 2024

The Debate Over the Predictive Utility of PD-L1–Low Expression is Ongoing in ESCC